Company intelligence / Profile preview
KoBioLabs
Seoul, Seoul, South Koreakobiolabs.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
KoBioLabs develops functional probiotics and novel microbiome-based therapeutics. Its lead clinical candidate KBL‑697 has reached Phase II trials for plaque psoriasis. Other pipeline assets are at the preclinical stage targeting obesity, NASH, IBS, and immune-related diseases. The company also markets consumer probiotic products under brands such as Bioviom and Queens henna FOODOLOGY. It collaborates with partners like Celltrion on microbiome antibodies.
- Therapeutic areas
- GastroenterologyEndocrinologyDermatologyImmunology
- Modalities
- ProbioticsMicrobiota-based therapiesSmall molecule drugsChemical drugsAntibody (microbiome antibody)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Collaboration with Celltrion on a microbiome antibody program targeting IBS.
Beyond the preview
Go deeper on KoBioLabs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KoBioLabs.